Regulatory Conditions in French M&A Agreements (2026): Drafting FDI & Merger‑control Clauses Buyers and Sellers Need

Regulatory clauses m&a france sit at the heart of every cross‑border acquisition touching a French target in 2026, and getting them right is now a question of deal survival rather than boilerplate. Shifting merger‑control thresholds and a broadened foreign direct investment (FDI) screening regime have moved regulatory risk allocation from a back‑of‑the‑document afterthought to a front‑line negotiation issue. In‑house counsel and M&A deal teams increasingly need clause language that does more than reference “required clearances”, it must sequence filings, allocate risk, and provide clean exit mechanics when a regulator says no.

This guide sets out, step by step, how to draft, negotiate and stress‑test the regulatory conditions in your French SPA, with model clause language, timelines, required documents and a costs table. Model clauses below are illustrative and must be adapted with local counsel to the specific transaction.

1. Overview, what “regulatory conditions” cover in French M&A

The phrase “regulatory conditions” in a French sale and purchase agreement (SPA) is shorthand for the bundle of conditions precedent, covenants and remedies that manage the gap between signing and closing while mandatory or voluntary clearances are obtained. In a cross‑border transaction, those clearances typically span three distinct regimes: national or EU merger control, FDI screening administered through the Ministry of Economy, and sector‑specific permits (banking, insurance, defence, media, energy). Each regime has its own trigger, its own timetable and its own consequences for non‑compliance. A well‑drafted SPA does not treat them as a single “regulatory approval” line item; it maps each clearance separately, sequences them, and assigns responsibility for filing, cooperation and cost.

The purpose of regulatory clauses m&a france is to convert regulatory uncertainty into contractual certainty. They tell each party who files, when, on what terms the parties must cooperate, what remedies each side must accept, and what happens if clearance is refused or arrives with conditions attached. Drafted loosely, they create disputes at the worst possible moment; drafted precisely, they preserve deal certainty and reduce the chance of a stalled or collapsed transaction.

Scope: merger control vs FDI screening vs sectoral permits

These three regimes answer different questions and cannot be collapsed into one clause. Merger control asks whether the concentration harms competition and is assessed by the French competition authority (Autorité de la concurrence) or, above EU thresholds, by the European Commission. FDI screening asks whether a foreign investor acquiring control or influence over a sensitive French activity threatens public order, security or essential interests, and is handled by the Direction générale du Trésor within the Ministry of Economy. Sectoral permits, a banking licence transfer, an insurance portfolio approval, a defence authorisation, sit alongside both and follow their own regulators. A single deal can require all three, each with a separate condition precedent and timetable.

When regulatory conditions are decisive (deal value / sectoral sensitivity)

Regulatory conditions become decisive, rather than routine, when the target crosses merger‑control turnover thresholds, when the acquirer is non‑EU or state‑linked, or when the target operates in a listed sensitive sector. In those cases the regulatory clauses effectively govern whether the deal closes at all. Deal value amplifies the stakes: the larger the transaction, the greater the loss if clearance fails at the longstop date, and the more important reverse break fees and cost‑allocation mechanics become. Sectoral sensitivity works the same way, a low‑value target in defence electronics may attract more scrutiny than a large but benign consumer‑goods acquisition.

2. Eligibility, when merger control or FDI screening applies

Before drafting any regulatory clauses m&a france, the deal team must establish which regimes are engaged. That analysis drives whether a condition precedent is mandatory, advisable, or unnecessary, and it dictates the timetable the SPA must accommodate. Getting this wrong at the outset, for example, assuming a filing is voluntary when it is in fact mandatory, exposes the parties to gun‑jumping penalties and, in the FDI context, to potential nullity of the transaction.

Merger‑control triggers (jurisdictional thresholds and turnover tests)

French national merger control rests on the concentration provisions of the Code de commerce (notably Articles L. 430‑1 et seq.). Notification is mandatory where the parties’ turnover exceeds the applicable thresholds and the transaction constitutes a “concentration” (a lasting change of control). The analysis is turnover‑based: it looks at worldwide and French turnover of the undertakings concerned. Where EU‑dimension thresholds are met, jurisdiction shifts to the European Commission under the one‑stop‑shop principle, and the national filing generally falls away. Because thresholds and their interpretation are subject to change, the exact figures must be verified against the Autorité de la concurrence and the Code de commerce on Legifrance for the deal date.

FDI screening clause triggers and sector list

FDI screening applies where a foreign investor acquires control of, or a defined stake in, a French entity carrying out activities on the sensitive‑sector list, which spans defence, dual‑use technologies, energy, water, transport, telecommunications, public health, and increasingly data, critical raw materials and emerging technologies. The screening test differs by investor nationality: acquirers from outside the EU/EEA face a lower threshold for triggering review than intra‑EU investors. The FDI screening clause in the SPA must therefore identify the investor’s ultimate nationality and ownership chain, because that determines whether the filing is mandatory, and if so on what timetable.

The authoritative sector definitions and procedural routes are set out in the Code monétaire et financier and published by the Direction générale du Trésor.

Voluntary vs mandatory notifications (action checklist)

• Confirm the trigger. Establish whether turnover thresholds and control tests make the merger‑control filing mandatory, and whether the target’s activities and investor nationality make FDI screening mandatory.
• Consider a pre‑closing request. Where FDI applicability is uncertain, request a preliminary ruling from the Ministry of Economy on whether the deal falls within scope.
• Decide on voluntary filing. For borderline sensitive sectors or state‑linked investors, weigh a voluntary FDI notification to secure legal certainty against the additional time and scrutiny it invites.
• Document the reasoning. Record the eligibility analysis so the SPA condition precedent reflects the actual regulatory profile.

3. Step‑by‑step: drafting and negotiating regulatory clauses m&a france

The drafting task divides into three instruments that must work together: the condition precedent (which suspends closing until clearance), the covenants (which govern conduct and cooperation during the gap), and the remedies (which allocate the consequences of failure). Confusing these categories, treating a covenant as a condition, or a condition as a mere best‑efforts undertaking, is the most common source of post‑signing dispute. The steps below sequence the work.

Step 1, Pre‑deal diligence and regulatory map

Who leads: Buyer’s counsel, with seller cooperation. Typical duration: 1–3 weeks.

1. Identify every clearance the transaction requires, merger control (national or EU), FDI, and sectoral permits.
2. Confirm each trigger against turnover data, the sensitive‑sector list and investor nationality.
3. Estimate the realistic clearance timetable for each regime, including plausible extensions.
4. Produce a one‑page regulatory map that the SPA drafting will follow, identifying the longest pole in the tent, usually FDI or Phase II merger review.

Step 2, Drafting the condition precedent language (minimum required elements)

The condition precedent is the load‑bearing clause. At minimum it must specify each clearance by name and regime, define what “clearance” means (unconditional approval, approval with acceptable conditions, or lapse of the review period without objection, tacit clearance), and identify the longstop date by which all conditions must be satisfied or the deal falls away. A well‑drafted condition precedent addresses the following:

1. Identify each condition separately. List merger‑control clearance and FDI clearance as distinct conditions, each capable of being satisfied or waived independently.
2. Define satisfaction precisely. State whether tacit clearance (expiry of the statutory period) counts, and whether conditional clearance satisfies the condition or triggers a remedy analysis.
3. Set the longstop. Fix a realistic longstop date that accommodates a possible Phase II review and FDI extension, with a defined right to extend by mutual agreement.
4. Allocate the “acceptable conditions” threshold. Define the level of remedies (divestitures, behavioural commitments) the buyer is obliged to accept before it may treat the condition as failed, this is the single most negotiated element.
5. Address waiver. State who may waive a condition and in what circumstances, recognising that mandatory clearances cannot be waived as a matter of law.

Note that the “acceptable conditions” threshold, sometimes called a hell‑or‑high‑water clause at its most buyer‑adverse, is where sellers push for deal certainty and buyers push to preserve the value they are paying for.

Step 3, Drafting covenants, cooperation obligations and information undertakings

Covenants govern behaviour between signing and closing. The regulatory covenants should:

1. Set the standard of effort. Specify “best efforts,” “reasonable best efforts,” or “all actions necessary,” and define what that standard requires in practice, this calibrates the buyer’s obligation to accept remedies.
2. Allocate filing responsibility. State who prepares and submits each filing, who controls strategy, and who leads regulator contact.
3. Impose cooperation and information duties. Require the seller and target to provide financials, market data and documents promptly, with confidentiality protections and clean‑team arrangements for competitively sensitive information.
4. Include conduct‑of‑business covenants. Prevent the target from taking gun‑jumping steps or material actions that could prejudice clearance during the review period.

Step 4, Remedies and exit mechanics (reverse break fees, specific performance, escrow)

Remedies decide who bears the loss when clearance fails or arrives with unacceptable conditions. The SPA should provide:

1. Termination rights. A clean right for either party to terminate if conditions are unsatisfied by the longstop, with defined consequences.
2. Reverse break fee. A pre‑agreed sum payable, typically by the buyer where regulatory failure is within its risk allocation, to compensate the seller for a failed deal and to incentivise the buyer to accept remedies.
3. Specific performance. Where enforceable, an obligation to complete once conditions are met, preventing a buyer from walking away opportunistically.
4. Escrow and holdbacks. Mechanisms to fund reverse break fees or remedy‑implementation costs on closing.

Step 5, Practical negotiation levers and red‑flags checklist

• The efforts standard. The buyer wants a soft standard; the seller wants “all necessary actions” up to a divestiture cap.
• The remedies cap. Define precisely how much divestment or behavioural commitment the buyer must swallow before the condition is treated as failed.
• The longstop and extensions. An unrealistically short longstop transfers regulatory risk to whichever party benefits from a lapse, negotiate deliberately.
• Reverse break fee quantum. Size it to genuinely incentivise cooperation without becoming a penalty a court might reduce.

4. Required documents for notifications

Both merger‑control and FDI notifications are document‑intensive. Assembling the file early is the single most effective way to compress the pre‑filing timeline, because regulators will not start the clock until they consider a notification complete. The following materials are typically required.

Practical tips on compiling transaction schedules and confidentiality packaging

Package competitively sensitive information, customer lists, pricing, margins, behind clean‑team protocols so it never reaches the acquirer’s commercial staff before closing. Prepare confidential and non‑confidential versions of each submission, because regulators may need to share the file with third parties during market testing. Build the document schedules into the SPA disclosure process so the same data set serves both due diligence and the notification, avoiding duplicate work and inconsistency between filings.

5. Timeline & deadlines

The SPA must reflect the real regulatory clock, not an optimistic one. The table below sets out an indicative sequence; all durations must be verified against current regulator guidance and the facts of the specific deal.

Extensions, deadlines, suspension options and tacit clearances

Two features must be reflected in the drafting. First, tacit clearance: where a statutory review period expires without an objection, clearance may be deemed granted, the condition precedent should expressly recognise this so the deal is not held hostage to a formal decision that never arrives. Second, stop‑the‑clock and extension mechanics: both merger‑control and FDI reviews can be extended (for example where commitments are offered or further information is required), and the SPA longstop must be long enough to absorb a Phase II or an extended FDI review. Draft the longstop with a defined, mutual right to extend so a foreseeable delay does not automatically collapse the deal.

Verify the current statutory periods on the Autorité de la concurrence and Direction générale du Trésor pages before finalising.

6. Costs and filing fees

Budget for regulatory cost as a discrete line in the deal model, separate from general legal spend. The table gives indicative ranges only; exact figures vary by case and must be confirmed on the regulator pages.

Budgeting for advisers, translation and remedies

The largest and least predictable cost is remedies. Where the competition authority imposes a divestiture or behavioural commitment, the cost of implementation and ongoing monitoring can dwarf adviser fees. The SPA should allocate that cost explicitly rather than leaving it to be argued after clearance. Translation is a smaller but real cost in cross‑border deals, since supporting documents must often be submitted in French.

7. What changes in 2026, drafting implications for regulatory clauses m&a france

The 2026 environment sharpens the case for careful regulatory drafting. Adjustments to merger‑control thresholds and an expanded FDI screening perimeter mean the set of transactions caught by these regimes is shifting, and more borderline deals face a genuine choice between filing and not filing. The practical effect, industry observers expect, is that regulatory conditions will feature in a wider band of deals that previously closed without them. For guidance on when a deal crosses the line into needing specialist support, see the GLE analysis on when do I need a cross‑border M&A lawyer in France.

Threshold shifts and tactical consequences

Where thresholds move, the eligibility analysis in Step 1 must be re‑run for the deal date rather than relying on last year’s figures, the exact 2026 values should be confirmed on the Code de commerce via Legifrance and the Autorité de la concurrence. Tactically, threshold change alters who bears regulatory risk: a deal newly caught by mandatory notification needs a condition precedent it might previously have omitted, and a longstop that accommodates the review period; conversely, a deal that falls out of scope may no longer need a suspensive condition at all. Deal teams that carry forward last year’s precedent without checking eligibility risk drafting a deal that is either over‑conditioned (delaying a clearance‑free transaction) or under‑conditioned (gun‑jumping exposure).

Evolving FDI practice and increased voluntary filings

The broadening of the FDI perimeter, coupled with sharper enforcement, is driving more voluntary notifications where applicability is genuinely uncertain. Deal teams increasingly prefer the certainty of a voluntary filing, accepting some additional time and scrutiny, over the risk of a post‑closing challenge that could unwind the transaction. This trend is consistent with the broader international movement toward more assertive investment screening tracked by the OECD. In drafting terms, it means the FDI screening clause should be flexible enough to accommodate a voluntary route, with cooperation covenants that apply whether the filing is mandatory or elective.

8. Common pitfalls and negotiation traps

Most regulatory‑clause disputes trace back to a handful of recurring drafting errors. Anticipating them at the negotiation stage is far cheaper than litigating them at the longstop.

Over‑broad conditions, ambiguous timelines, poor covenants

• Over‑broad conditions. A condition that lets a buyer walk away on any regulatory objection, however trivial, destroys the seller’s deal certainty and invites opportunistic termination, cap the remedies the buyer must accept instead.
• Ambiguous timelines. A longstop that fails to define whether it captures tacit clearance, extensions or a possible Phase II leaves both parties guessing when the deal dies.
• Weak cooperation covenants. If the seller has no clear obligation to supply data promptly, the buyer’s filing stalls and the buyer bears blame for a delay it cannot control.
• Undefined efforts standard. “Best efforts” without a remedies cap can be read as a hell‑or‑high‑water obligation the buyer never intended to give.

Sample redlines and safe alternatives

• Replace “the Buyer shall obtain all clearances” with “the Buyer shall use reasonable best efforts to obtain the Clearances, provided that the Buyer shall not be required to accept remedies exceeding [defined cap].”
• Replace “clearance shall be obtained by the Longstop Date” with a definition that treats expiry of the statutory review period without objection as satisfaction, and that provides a mutual extension right for a Phase II or extended FDI review.
• Add an express information‑cooperation covenant with deadlines and clean‑team protection, rather than relying on a general good‑faith clause.

9. Model clause bank (practical examples)

The clauses below are illustrative drafting starting points only. Adapt each with French local counsel to the specific transaction, regime and 2026 threshold position.

Condition precedent, merger control clearance clause (buyer‑friendly and seller‑friendly variants)

Buyer‑friendly variant: “Completion is conditional upon the Autorité de la concurrence (or, where applicable, the European Commission) having granted clearance of the Transaction unconditionally, or subject only to conditions, commitments or remedies that, individually or in aggregate, do not require the Buyer to divest assets or accept obligations that the Buyer, acting reasonably, determines to be material.”

Seller‑friendly variant: “Completion is conditional upon Clearance, which shall be deemed obtained upon the earlier of a decision granting clearance and the expiry of the applicable statutory review period without objection. The Buyer shall use all reasonable best efforts to obtain Clearance and shall accept any remedies necessary to secure it, save where such remedies would require divestment exceeding [X]% of the target turnover.”

FDI screening clause (model text + commentary)

Model text: “Completion is conditional upon the Minister of Economy having (i) confirmed that the Transaction does not require authorisation under the applicable foreign investment control regime, or (ii) granted authorisation, whether unconditionally or subject to conditions acceptable to the Buyer acting reasonably, or (iii) failed to object within the applicable statutory period such that authorisation is deemed granted. The Buyer shall submit the notification (or request for preliminary ruling) within [X] Business Days of the date of this Agreement and shall keep the Seller reasonably informed of its progress.”

Commentary: This clause deliberately covers all three outcomes, non‑applicability confirmation, express authorisation and tacit clearance, because in a cross‑border deal the applicability question itself is often uncertain. The notification deadline protects the seller against a buyer that delays filing to preserve an exit. Confirm the current statutory period and notification route with the Direction générale du Trésor before use.

Reverse break fee clause + calculation example

Model text: “If Completion does not occur solely because a Regulatory Condition has not been satisfied by the Longstop Date, the Buyer shall pay the Seller a reverse break fee of EUR [amount] within [X] Business Days of termination, as compensation for the Seller’s costs and lost opportunity.”

Worked example: On a EUR 100m enterprise‑value deal, a reverse break fee expressed as a low‑single‑digit percentage of enterprise value is a common order of magnitude in market practice. It should be large enough to incentivise the buyer to accept reasonable remedies, but calibrated in light of the fact that French courts may reduce a penalty clause (clause pénale) that is manifestly excessive. Fund it through an escrow or a parent guarantee where the buyer is a special‑purpose vehicle.

Comparison: voluntary vs mandatory notification

Conclusion

Regulatory clauses m&a france have become the decisive risk‑allocation mechanism in French cross‑border transactions, and the 2026 threshold and FDI screening changes make precise drafting more important than ever. The disciplined path is to map every clearance at the outset, draft each condition precedent separately and precisely, calibrate the efforts standard and remedies cap, and back the whole structure with clean exit mechanics and a properly sized reverse break fee. Deal teams that treat regulatory conditions as a single boilerplate line will find themselves negotiating the hard questions at the longstop, when leverage has evaporated; those that draft them deliberately preserve deal certainty and protect value.

Because thresholds, statutory periods and any applicable fees are subject to change, verify every procedural figure against the Autorité de la concurrence, the Code de commerce on Legifrance and the Direction générale du Trésor for the specific deal date, and have French local counsel review any model clause before use.

Sources

1. Autorité de la concurrence, Mergers
2. Legifrance, Code de commerce
3. Direction générale du Trésor (Ministry of Economy), foreign investment control
4. European Commission, Merger control overview
5. Conseil d’État
6. OECD, Investment and FDI policy guidance